Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2010. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding changes in their interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the share price of £12.20 per ordinary share at the time of the transaction.
Material Changes
On May 4, 2010, the following individuals purchased ordinary shares through the reinvestment of dividends within an Individual Savings Account (ISA):
- Mr A P Witty: 17 shares
- Mr J S Heslop: 9 shares
- Mr S M Bicknell: 68 shares
- Mr E J Gray: 8 shares
- Mr D S Redfern: 8 shares
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It is strictly a regulatory disclosure of director share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Confirm the total number of shares held by each director following this transaction.
- Verify the current share price relative to the £12.20 transaction price.
- Review the company's Form 20-F for comprehensive financial performance data, as this filing does not contain it.